Nimotuzumab’s low toxicity profile has made possible the intent of using an anti-EGFR agent in continuous, long-term treatment (lasting several months, and a few years in several cases), which has so far been administered to a few hundred advanced cancer patients (Perez et al., 2011). The gene discussed is EGFR; the disease is cancer.